Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it distinguishes itself from others pursuing RNA interference strategies by also offering technology to deliver treatment to very specific locations within the body.
Astellas Venture Management led this most recent tranche, which… Continue Reading
Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures, MediBic Alliance Technology Fund and Novartis Venture Fund.
The Palo Alto, Calif.-based company has developed an RNA interference therapy for cancer, as well as a mode for delivering it to the… Continue Reading
Life-science briefing: Thursday, April 10, 2008
TODAY’S HEADLINES:
HealthExtras buys venture-backed PBM HospiScript for $100M (release)
Urological device-maker NeoTract adds $7.4M (VentureWire)
RNAi-drug startup Intradigm seeks $35M (VentureWire)
Israel’s Arbel Medical raises $3.5M for tumor cryotherapy (release)
HealthExtras buys venture-backed PBM HospiScript for $100M — HospiScript Services, a Montgomery, Ala., prescription-benefits manager, agreed to be acquired by HealthExtras of Rockville, Md. HealthExtras will pay $100 million in cash for the venture-backed firm, which services the hospice industry.
HospiScript had raised at least $4 million in funding, according… Continue Reading
Intradigm, a gene targeting co., raises $16M
Intradigm, a Palo Alto biotech company that is using a technology called “RNA interference” (RNAi) to target genes while providing oncology medical treatments, has raised $16 million in a first round of funding.
It has also moved to Palo Alto, from Rockville, Maryland, driven by the need for better research and development talent, it said.
The round, which occurred in May 2006 was co-led by Alta
Partners and Frazier Healthcare Ventures. Existing investors Emerging Technology Partners (ETP) and… Continue Reading